Delving into the Latest Updates on The First Hospital of Jilin University with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Other Diseases

Small molecule drug

Antibody drug conjugate (ADC)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Nervous System Diseases	2
Infectious Diseases	2
Immune System Diseases	2
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	4
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

EGFR(Epidermal growth factor receptor erbB1)	1
TLR7 x TLR9	1
NS3/NS4A(Hepatitis C virus serine protease, NS3/NS4A)	1

Current therapeutic strategies for ischemic stroke fall short of the desired objective of neurological functional recovery. Therefore, there is an urgent need to develop new methods for the treatment of this condition. Exosomes are natural cell-derived vesicles that mediate signal transduction between cells under physiological and pathological conditions. They have low immunogenicity, good stability, high delivery efficiency, and the ability to cross the blood–brain barrier. These physiological properties of exosomes have the potential to lead to new breakthroughs in the treatment of ischemic stroke. The rapid development of nanotechnology has advanced the application of engineered exosomes, which can effectively improve targeting ability, enhance therapeutic efficacy, and minimize the dosages needed. Advances in technology have also driven clinical translational research on exosomes. In this review, we describe the therapeutic effects of exosomes and their positive roles in current treatment strategies for ischemic stroke, including their anti-inflammation, anti-apoptosis, autophagy-regulation, angiogenesis, neurogenesis, and glial scar formation reduction effects. However, it is worth noting that, despite their significant therapeutic potential, there remains a dearth of standardized characterization methods and efficient isolation techniques capable of producing highly purified exosomes. Future optimization strategies should prioritize the exploration of suitable isolation techniques and the establishment of unified workflows to effectively harness exosomes for diagnostic or therapeutic applications in ischemic stroke. Ultimately, our review aims to summarize our understanding of exosome-based treatment prospects in ischemic stroke and foster innovative ideas for the development of exosome-based therapies.

01 Jan 2025·Colloids and Surfaces B: Biointerfaces

Cell membrane-functionalized bismuth oxyiodide nanodots as potential contrast agent for gastrointestinal tract imaging

Article

Author: Jiang, Xin ; Jin, Limin ; Ling, Yunyan ; Jin, Meng ; Li, Quanxiao ; Wang, Xuecen

Various noninvasive imaging modalities, including X-ray and computed tomography (CT) imaging, have provided significant advantages in accurately assessing the conditions of the gastrointestinal (GI) tract. The corresponding contrast agent with high resolution and biosafety is one of the most crucial focuses in the diagnosis of GI diseases. In this study, considering the requirements of good biocompatibility and biosafety, a novel imaging platform composed of the high-performance contrast agent based on macrophage membrane-coated BiOI nanodots (BiOI@M) was designed via a facile approach. The BiOI@M exhibited outstanding long-term stability and low toxicity. Significantly, BiOI@M demonstrated superior imaging ability compared to clinical barium sulfate. Higher CT values of BiOI@M were observed at equivalent concentrations to barium sulfate, thereby clearly outlining the stomach, small intestine, caecum, and colon after the oral administration of BiOI@M solutions in X-ray and CT imaging. Taken together, BiOI@M could serve as a novel efficient contrast agent in X-ray/CT imaging of the GI tract and diagnosis of GI diseases.

01 Jan 2025·Journal of Colloid and Interface Science

A wearable iontophoresis enables dual-responsive transdermal delivery for atopic dermatitis treatment

Article

Author: Chao, Danming ; Pang, Daxin ; Xin, Meiying ; Jia, Xiaoteng ; Yuan, Hongming ; Zhou, Yan ; Xiang, Hongyong ; Li, Runan ; Liang, Qin

Atopic dermatitis is a chronic, inflammation skin disease that remains a major public health challenge. The current drug-loading hydrogel dressings offer numerous benefits with enhanced loading capacity and a moist-rich environment. However, their development is still limited by the accessibility of a suitable driven source outside the clinical environment for precise control over transdermal delivery kinetics. Here, we prepare a sulfonated poly(3,4-ethylenedioxythiophene) (PEDOT) polyelectrolyte hydrogel drug reservoir that responds to different stimuli-both endogenous cue (body temperature) and exogenous cue (electrical stimulation), for wearable on-demand transdermal delivery with enhanced efficacy. Functioned as both the drug reservoir and cathode in a Zn battery-powered iontophoresis patch, this dual-responsive hydrogel achieves high drug release efficiency (68.4 %) at 37 °C. Evaluation in hairless mouse skin demonstrates the efficacy of this technology by facilitating transdermal transport of 12.2 μg cm^-2 dexamethasone phosphate when discharged with a 10³ Ω external resistor for 3 h. The Zn battery-driven iontophoresis results in an effective treatment of atopic dermatitis, displaying reductions in epidermal thickness, mast cell infiltration inhibition, and a decrease in IgE levels. This work provides a new treatment modality for chronic epidermal diseases that require precise drug delivery in a non-invasive way.

100 Deals associated with The First Hospital of Jilin University

Login to view more data

100 Translational Medicine associated with The First Hospital of Jilin University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

1

Phase 3 Clinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Seraprevir ( NS3/NS4A )	Hepatitis C More	Phase 3
AGCM-22 ( EGFR )	Glioblastoma More	Preclinical
HJ901 ( TLR7 x TLR9 )	Diffuse Large B-Cell Lymphoma More	Preclinical
Ascorbic Acid	Multiple Myeloma More	Preclinical
ZBH-01	Colonic Cancer More	Preclinical